Potential role of CXCL13/CXCR5 signaling in immune checkpoint inhibitor treatment in cancer
CH Hsieh, CZ Jian, LI Lin, GS Low, PY Ou, C Hsu… - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy is currently the backbone of new drug treatments for many
cancer patients. CXC chemokine ligand 13 (CXCL13) is an important factor involved in …
cancer patients. CXC chemokine ligand 13 (CXCL13) is an important factor involved in …
[HTML][HTML] Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives
G Cui - Biomedicine & Pharmacotherapy, 2022 - Elsevier
To date, immune checkpoint blockade (ICB) immunotherapy has become one of promise
strategies in the management of patients with unresectable or metastatic colorectal cancer …
strategies in the management of patients with unresectable or metastatic colorectal cancer …
[HTML][HTML] Unique patterns of heterogeneous mismatch repair protein expression in colorectal cancer unveil different degrees of tumor mutational burden and distinct …
E Berrino, MC Aquilano, E Valtorta, V Amodio… - Modern Pathology, 2023 - Elsevier
Mismatch repair (MMR) protein expression in colorectal cancer (CRC) cells is usually
homogeneously retained or lost. Rare lesions may show a heterogeneous pattern of MMR …
homogeneously retained or lost. Rare lesions may show a heterogeneous pattern of MMR …
Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or …
C Nie, H Lv, B Chen, W Xu, J Wang, Y Liu… - Frontiers in …, 2022 - frontiersin.org
Objectives The antitumor activity of nivolumab plus regorafenib in colorectal cancer from a
phase Ib REGONIVO study is encouraging. The present study was conducted to evaluate …
phase Ib REGONIVO study is encouraging. The present study was conducted to evaluate …
Risk scoring based on DNA methylation-driven related DEGs for colorectal cancer prognosis with systematic insights
Colorectal cancer is a common malignant tumor of the digestive tract. Despite advances in
diagnostic techniques and medications. Its prognosis remains challenging. DNA methylation …
diagnostic techniques and medications. Its prognosis remains challenging. DNA methylation …
[HTML][HTML] When will the Immune-Stimulating Antibody Conjugates (ISACs) be transferred from bench to bedside?
C Fu, W Tong, L Yu, Y Miao, Q Wei, Z Yu… - Pharmacological …, 2024 - Elsevier
Immunostimulatory antibody conjugates (ISACs) as a promising new generation of targeted
therapeutic antibody-drug conjugates (ADCs), that not only activate innate immunity but also …
therapeutic antibody-drug conjugates (ADCs), that not only activate innate immunity but also …
BTN3A: A promising immune checkpoint for cancer prognosis and treatment
A Kone, S Ait Ssi, S Sahraoui, A Badou - International Journal of …, 2022 - mdpi.com
Butyrophilin-3A (BTN3A) subfamily members are a group of immunoglobulins present on the
surface of different cell types, including innate and cancer cells. Due to their high similarity …
surface of different cell types, including innate and cancer cells. Due to their high similarity …
Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment
F Wang, S Lu, X Zhou, X Di, R Wu, G Chen… - Frontiers in …, 2023 - frontiersin.org
Background Stage II colorectal cancer (CRC) patients after surgery alone have a five-year
survival rate of~ 60-80%; the incremental benefit of adjuvant chemotherapy is< 5 …
survival rate of~ 60-80%; the incremental benefit of adjuvant chemotherapy is< 5 …
[PDF][PDF] Die Interaktion von T-Zellen und autologen kolorektalen Tumorzellen: Charakterisierung immunsuppressiver Mechanismen und Verbesserung der …
S Schwarz - 2022 - rosdok.uni-rostock.de
Ursächlich für das KRK sind meist gutartige Adenome, die aufgrund genetischer
Veränderungen entarten und in ein malignes Wachstum übergehen. Dieser als Adenom …
Veränderungen entarten und in ein malignes Wachstum übergehen. Dieser als Adenom …